Proteomics of serum-derived extracellular vesicles are associated with the severity and different clinical profiles of patients with COVID-19: An exploratory secondary analysis

Autor(es):Mostrar menos -

Leme, Adriana F. Paes ; Yokoo, Sami ; Normando, Ana Gabriela C. ; Ormonde, Jao Vitor S. ; Domingues, Romenia Ramos ; Cruz, Fernanda F. ; Silva, Pedro L. ; Souza, Bruno S. F. ; Santos, Claudia C. dos ; Castro-Faria-Neto, Hugo ; Martins, Camila Marinelli ; Lopes-Pacheco, Miqueias ; Rocco, Patricia R. M.

• Tipo de documento: Artigo Científico
• Fonte: CYTOTHERAPY; v. 26, n. 5, p. 12-pg., 2024-04-30.

Resumo

Background aims: Coronavirus disease 2019 (COVID-19) is characterized by a broad spectrum of clinical manifestations with the potential to progress to multiple organ dysfunction in severe cases. Extracellular vesicles (EVs) carry a range of biological cargoes, which may be used as biomarkers of disease state. Methods: An exploratory secondary analysis of the SARITA-2 and SARITA-1 datasets (randomized clinical trials on patients with mild and moderate/severe COVID-19) was performed. Serum-derived EVs were used for proteomic analysis to identify enriched biological processes and key proteins, thus providing insights into differences in disease severity. Serum-derived EVs were separated from patients with COVID-19 by size exclusion chromatography and nanoparticle tracking analysis was used to determine particle concentration and diameter. Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was performed to identify and quantify protein signatures. Bioinformatics and multivariate statistical analysis were applied to distinguish candidate proteins associated with disease severity (mild versus moderate/severe COVID-19). Results: No differences were observed in terms of the concentration and diameter of enriched EVs between mild (n = 14) and moderate/severe (n = 30) COVID-19. A total of 414 proteins were found to be present in EVs, of which 360 were shared while 48 were uniquely present in severe/moderate compared to mild COVID-19. The main biological signatures in moderate/severe COVID-19 were associated with platelet degranulation, exocytosis, complement activation, immune effector activation, and humoral immune response. Von Willebrand factor, serum amyloid A-2 protein, histone H4 and H2A type 2-C, and fibrinogen b -chain were the most differentially expressed proteins between severity groups. Conclusion: Exploratory proteomic analysis of serum-derived EVs from patients with COVID-19 detected key proteins related to immune response and activation of coagulation and complement pathways, which are associated with disease severity. Our data suggest that EV proteins may be relevant biomarkers of disease state and prognosis. (c) 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 19/09692-9 - Validação de proteínas-alvo associadas à progressão de lesões potencialmente malignas para Câncer Oral
• Beneficiário: Ana Gabriela Costa Normando
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 20/11709-4 - Combinação de estratégias ômicas pode indicar potenciais alvos envolvidos na iniciação de Câncer Oral por meio da comunicação de vesículas extracelulares
• Beneficiário: João Vitor Silva Ormonde
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 09/54067-3 - EMU: aquisição de um espectrômetro de massas acoplado a cromatografia líquida para permitir ampliar a capacidade de atendimento de usuários e disponibilizar novas tecnologias no Laboratório de Espectrometria de Massas do Centro de Biologia Molecular Estrutural (ABTLUS)
• Beneficiário: Adriana Franco Paes Leme
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 18/18496-6 - O papel do álcool na transformação de células orais mediada por vesículas extracelulares
• Beneficiário: Adriana Franco Paes Leme
• Modalidade de apoio: Auxílio à Pesquisa - Temático